Literature DB >> 8758923

Microsatellite analysis of endometriosis reveals loss of heterozygosity at candidate ovarian tumor suppressor gene loci.

X Jiang1, A Hitchcock, E J Bryan, R H Watson, P Englefield, E J Thomas, I G Campbell.   

Abstract

Endometriosis is a very common gynecological condition in which tissue similar to endometrium proliferates at sites outside the uterine cavity, most commonly the ovary. Although it generally remains a benign condition, malignant transformation has been documented. and it is commonly found in association with endometrioid subtype ovarian cancer. Tumor suppressor genes are commonly altered in ovarian cancers, and the development of endometriosis may involve mutations in the same class of genes. We have investigated this possibility by examining DNA from 40 cases of endometriosis for clonal status, alterations in TP53 and RASK, and allelic losses at candidate ovarian tumor suppressor loci on chromosome arms 6q, 9p, l1q, 17p, l7q, and 22q. The majority of endometriotic cysts were monoclonal, but interestingly, 8 of 10 normal endometrial glands were also monoclonal, demonstrating that both are able to develop from a single progenitor cell. No mutations were detected in TP53 or RASK. Loss of heterozygosity (LOH) was detected on chromosomes 9p (18%), 1lq (18%), and 22q (15%). In total, 11 of 40 (28%) cases demonstrated LOH at one or more of these loci. This study, which is the first to report LOH in endometriosis, supports the notion that tumor suppressor gene inactivation may play a role in the development of at least a subset of cases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8758923

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

Review 1.  The clonal origin and clonal evolution of epithelial tumours.

Authors:  S B Garcia; M Novelli; N A Wright
Journal:  Int J Exp Pathol       Date:  2000-04       Impact factor: 1.925

2.  p21 gene codon 31 arginine/serine polymorphism: non-association with endometriosis.

Authors:  Y Y Hsieh; F J Tsai; C C Chang; W C Chen; C H Tsai; H D Tsai; C C Lin
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

Review 3.  The Stem Cell Network model: clinical implications in cancer.

Authors:  Rubén Cabanillas; José L Llorente
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-09-20       Impact factor: 2.503

Review 4.  Ovarian cancer in endometriosis: clinical and molecular aspects.

Authors:  B Lyttle; L Bernardi; M E Pavone
Journal:  Minerva Ginecol       Date:  2014-04

5.  Genetics and genomics of endometriosis.

Authors:  Keith A Hansen; Kathleen M Eyster
Journal:  Clin Obstet Gynecol       Date:  2010-06       Impact factor: 2.190

6.  Evaluation of miR-135a/b expression in endometriosis lesions.

Authors:  Rafaella Petracco; Ana Cristina De Oliveira Dias; Hugh Taylor; Álvaro Petracco; Mariângela Badalotti; João Da Rosa Michelon; Daniel Rodrigo Marinowic; Marta Hentschke; Pamella Nunes De Azevedo; Gabriele Zanirati; Denise Cantarelli Machado
Journal:  Biomed Rep       Date:  2019-09-02

7.  Endometriosis research using capture microdissection techniques: Progress and future applications.

Authors:  Luyang Zhao; Chenglei Gu; Ke Huang; Weidong Han; Meng Fu; Yuanguang Meng
Journal:  Biomed Rep       Date:  2016-09-15

8.  Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma.

Authors:  Wenbin Xiao; Amad Awadallah; Wei Xin
Journal:  Int J Clin Exp Pathol       Date:  2012-09-05

9.  The role of components of the chromatin modification machinery in carcinogenesis of clear cell carcinoma of the ovary (Review).

Authors:  Hiroshi Shigetomi; Akira Oonogi; Taihei Tsunemi; Yasuhito Tanase; Yoshihiko Yamada; Hirotaka Kajihara; Yoriko Yoshizawa; Naoto Furukawa; Shoji Haruta; Shozo Yoshida; Toshiyuki Sado; Hidekazu Oi; Hiroshi Kobayashi
Journal:  Oncol Lett       Date:  2011-05-16       Impact factor: 2.967

Review 10.  [Endometriosis-related ovarian tumors].

Authors:  D Schmidt; U Ulrich
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.